| Literature DB >> 35597948 |
Augusta Silveira1,2, Teresa Sequeira1,2, Joaquim Gonçalves3, Pedro Lopes Ferreira4,5.
Abstract
In public health context, oncology is associated with severe negative impact on patients and on their relatives' quality of life. Over the last decades, survival has remained at 50% worldwide for some tumor locations. Patient reported outcomes (PROs) assessment and, the corresponding use in clinical practice, help establishing patient individualized profiling involving caregivers. The purpose of this systematic review was to examine critical success factors for PROs assessment in daily clinical oncology practice. Additionally, we investigated how PROs collection can change oncology perspectives for patients and caregivers. According to PRISMA guidelines, 83 studies were included in this systematic review, whether related with implementation in daily clinical practice or associated with its use in oncology. PROs assessment gathers multi-professional teams, biomedical and clinical expertise, patients, families and caregivers. Institutional involvement, first line for caregiver's adherence, team continuous formation, encompassing training and support, design of clear workflows, continuous monitoring, and data analysis are crucial for implementation. PROs measures are decisive in oncology. Several items were improved, including caregiver-patient-physician communication, patient risk groups identification, unmet problems and needs detection, disease course and treatment tracking, prognostic markers, cost-effectiveness measurement and comfort/support provision for both patients and caregivers. Routine assessment and implementation of PROs in clinical practice are a major challenge and a paradigm transformation for future.Entities:
Keywords: Caregivers; Critical success factors; Implementation; Oncology; Patient reported outcomes
Mesh:
Year: 2022 PMID: 35597948 PMCID: PMC9124403 DOI: 10.1186/s12955-022-01987-x
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.077
Fig. 1PRISMA flow diagram
Study characteristics of all studies (N = 83)
| Characteristics | Classification | N (%) |
|---|---|---|
| Study design | Systematic review (SR) | 27 (32.5%) |
| Research article (RA) | 21 (25.3%) | |
| Retrospective, prospective (RP) | 35 (42.2%) | |
| Based on HRQoL | 47 (56.6%) | |
| Oncology perspectives interest | High (H) | 70 (86.4%) |
| Moderate (M) | 11 (13.6%) | |
| Low (L) | 0 (0.0%) | |
| Oncology implementation interest | High (H) | 55 (88.7%) |
| Moderate (M) | 7 (11.3%) | |
| Low (L) | 0 (0.0%) |
Selected articles type and rated interest considering the published year (%)
| Type of article | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|---|---|
| HQoL | 14.3 | 14.3 | 37.6 | 20.0 | 29.4 | 22.5 | 17.9 | 20.5 | 30.8 |
| Systematic reviews | 14.3 | 21.4 | 0.0 | 30.0 | 14.7 | 10.0 | 12.8 | 5.1 | 15.4 |
| Research | 0.0 | 0.0 | 18.8 | 0.0 | 11.8 | 7.5 | 12.8 | 7.7 | 7.7 |
| Retrospective and prospective | 19.1 | 21.4 | 25.0 | 10.0 | 8.8 | 20.0 | 15.4 | 31.0 | 7.7 |
| High interest | 19.1 | 35.7 | 31.3 | 30.0 | 17.6 | 32.5 | 23.1 | 33.3 | 38.5 |
| Moderate interest | 9.5 | 7.1 | 8.3 | 10.0 | 17.6 | 5.0 | 17.9 | 5.1 | 0.0 |
PROs: oncology perspectives
| N (%) | Perspectives | N (%) | |
|---|---|---|---|
| Oncology patients | 67 (87.7%) | Stepped care models | 28 (41.8%) |
| Prognosis value | 34 (50.7%) | ||
| Communication | 37 (55.2%) | ||
| Patient safety | 40 (59.7%) | ||
| Risk identification | 50 (74.6%) | ||
| Caregivers | 21 (25.3%) | Communication improvements | 7 (33.3%) |
| Supportive care guidance | 7 (33.3%) | ||
| Caregiver support and unmet needs identification | 14 (66.7%) | ||
| Caregiver burden | 16 (76.2%) | ||
| Health systems, communities and society | 63 (75.9%) | Futures perspectives in oncology | 40 (63.5%) |
| Economical decisions, cost-effective measures | 4 (6.3%) | ||
| Drug approval | 4 (6.3%) | ||
| Patient centered care | 51 (81.0%) |
The percentages’ sum can be higher than 100% since some articles addressed several domains
PROs implementation perspectives
| N (%) | Perspectives | N (%) | |
|---|---|---|---|
| Critical success factors | 23 (27.7%) | Staff involvement | 17 (73.9%) |
| Institution approval | 11 (47.8%) | ||
| Clear workflows | 18 (78.3%) | ||
| Team continuous formation | 12 (52.2%) | ||
| Data analysis | 16 (69.6%) | ||
| Implementation methodology | 22 (26.5%) | Research intervention | 12 (54.5%) |
| Clinical interventions | 20 (90.9%) | ||
| Medical interventions | 13 (59.1%) | ||
| Physiological interventions | 8 (36.4%) | ||
| Social interventions | 2 (9.1%) | ||
| Routine clinical practice | 62 (74.7%) | Use for clinical purposes | 46 (74.2%) |
| Use for research purposes | 19 (30.6%) | ||
| Use for economical purposes | 8 (12.9%) | ||
| Quality of care | 49 (79.0%) |
The percentages’ sum can be higher than 100% since some articles addressed several domains
Proportion of articles found for each perspective considered and assigned interest (%)
| HRQoL | Systematic reviews | Research | Retrospective and protective | High interest | Moderate interest | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | |
| Oncology patients | ||||||||||||
| Stepped care models | 32.4 | 37.7 | 27.6 | 48.0 | 42.2 | 5.3 | 32.6 | 35.0 | 18.2 | 39.3 | 38.7 | 19.0 |
| Prognosis value | 26.5 | 51.0 | 41.4 | 40.0 | 45.3 | 26.3 | 34.9 | 47.5 | 27.3 | 49.5 | 45.5 | 28.6 |
| Communication | 44.1 | 44.9 | 46.6 | 40.0 | 51.6 | 21.1 | 34.9 | 55.0 | 22.7 | 52.5 | 51.6 | 28.8 |
| Patient safety | 52.9 | 44.9 | 53.4 | 36.0 | 51.6 | 36.8 | 39.5 | 57.5 | 27.3 | 55.7 | 54.8 | 28.6 |
| Risk identification | 50.0 | 67.3 | 63.8 | 52.0 | 65.6 | 42.1 | 51.2 | 70.0 | 50.0 | 63.9 | 62.9 | 52.4 |
| Caregivers | ||||||||||||
| Communication improvements | 8.8 | 8.2 | 10.3 | 4.0 | 6.3 | 15.8 | 7.0 | 10.0 | 9.1 | 8.2 | 8.1 | 9.5 |
| Supportive care guidance | 11.8 | 6.1 | 10.3 | 4.0 | 7.8 | 10.5 | 4.7 | 12.5 | 9.1 | 8.2 | 8.1 | 9.5 |
| Caregiver support and unmet needs identification | 17.6 | 16.3 | 24.1 | 0.0 | 7.8 | 47.7 | 16.3 | 17.5 | 27.3 | 13.1 | 14.5 | 23.8 |
| Caregiver burden | 17.6 | 20.4 | 24.1 | 8.0 | 14.1 | 36.8 | 18.6 | 20.0 | 27.3 | 16.4 | 16.1 | 28.6 |
| Health systems | ||||||||||||
| Futures perspectives in oncology | 50.0 | 46.9 | 51.7 | 40.0 | 43.8 | 63.2 | 46.5 | 50.0 | 27.3 | 55.7 | 56.5 | 23.8 |
| Economical decisions, cost-effective measures | 8.8 | 2.0 | 3.4 | 8.0 | 6.3 | 0.0 | 4.7 | 5.0 | 4.5 | 4.9 | 4.8 | 4.8 |
| Drug approval | 5.9 | 4.1 | 1.7 | 12.0 | 6.3 | 0.0 | 7.0 | 2.5 | 0.0 | 6.6 | 6.5 | 0.0 |
| Patient centered care | 64.7 | 59.2 | 63.8 | 56.0 | 65.6 | 47.4 | 51.2 | 72.5 | 50.0 | 65.6 | 64.5 | 52.4 |
| Oncology patients | ||||||||||||
| Staff involvement | 20.6 | 20.4 | 24.1 | 12.0 | 21.9 | 15.8 | 14.0 | 27.5 | 0.0 | 27.9 | 27.4 | 0.0 |
| Institution approval | 14.7 | 12.2 | 19.0 | 0.0 | 15.6 | 5.3 | 2.3 | 25.0 | 0.0 | 18.0 | 17.7 | 0.0 |
| Clear workflows | 20.6 | 22.4 | 31.0 | 0.0 | 23.4 | 15.8 | 9.3 | 35.0 | 0.0 | 29.5 | 29.0 | 0.0 |
| Team continuous formation | 14.7 | 14.3 | 20.7 | 0.0 | 15.6 | 10.5 | 4.7 | 25.0 | 0.0 | 19.7 | 19.4 | 0.0 |
| Data analysis | 17.6 | 20.4 | 25.9 | 4.0 | 21.9 | 10.5 | 7.0 | 32.5 | 0.0 | 26.2 | 25.8 | 0.0 |
| Oncology patients | ||||||||||||
| Research intervention | 8.8 | 18.4 | 20.7 | 0.0 | 15.6 | 10.5 | 4.7 | 25.0 | 0.0 | 19.7 | 19.4 | 0.0 |
| Clinical interventions | 29.4 | 20.4 | 29.3 | 12.0 | 26.6 | 16.8 | 14.0 | 35.0 | 9.1 | 29.5 | 29.0 | 9.5 |
| Medical interventions | 14.7 | 16.3 | 22.4 | 0.0 | 17.2 | 10.5 | 4.7 | 27.5 | 0.0 | 21.3 | 21.0 | 0.0 |
| Physiological interventions | 5.9 | 12.2 | 13.8 | 0.0 | 10.9 | 5.3 | 2.3 | 17.5 | 4.5 | 11.5 | 11.3 | 4.8 |
| Social interventions | 0.0 | 4.1 | 3.4 | 0.0 | 1.6 | 5.3 | 2.3 | 2.5 | 0.0 | 3.3 | 3.2 | 0.0 |
| Oncology patients | ||||||||||||
| Use for clinical purposes | 55.9 | 55.1 | 56.9 | 52.0 | 57.8 | 47.4 | 48.8 | 62.5 | 27.3 | 65.6 | 66.1 | 23.8 |
| Use for research purposes | 20.6 | 24.5 | 27.6 | 12.0 | 23.4 | 21.1 | 16.3 | 30.0 | 4.5 | 29.5 | 29.0 | 4.8 |
| Use for economical purposes | 8.8 | 10.2 | 6.9 | 16.0 | 10.9 | 5.3 | 11.6 | 7.5 | 0.0 | 13.1 | 12.9 | 0.0 |
| Quality of care | 58.8 | 57.1 | 70.7 | 28.0 | 54.7 | 68.4 | 41.9 | 75.0 | 59.1 | 57.4 | 58.1 | 57.1 |